• Completed phase 2 study with 157 patients
  • RRMM patients with few or no remaining treatment options
  • Evaluating melflufen in combination with dexamethasone in RRMM patients
  • Patients have received >2 earlier lines of therapy with IMiDs and PIs and are refractory to pomalidomide and/or daratumumab
  • Basis for FDA submission for accelerated approval
  • Supports OCEAN for marketing authorization
  • Started in Q1 2017, data reporting in 2018/2019 and follow-up in 2019/2020